日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastases

对BRAF V600E阳性黑色素瘤伴脑转移患者进行多模式管理和分子谱分析

Gritsch, David; Fadden, Riley M; Mahar, Maura K; Khandsekar, Melin J; Oh, Kevin S; Cahil, Daniel P 3rd; Dunn, Gavin P; Sullivan, Ryan J; Brastianos, Priscilla K

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

2025年泌尿系统晚期肿瘤共识会议(AUC3):肾细胞癌和泌尿系统肿瘤治疗的专家共识

McKay, Rana R; Pal, Sumanta; Xie, Wanling; Aggen, David; Albiges, Laurence; Apolo, Andrea; Atkins, Michael B; Bangs, Rick; Beckermann, Kathryn E; Bellmunt, Joaquim; Berg, Stephanie A; Bilen, Mehmet A; Braun, David; Carlo, Maria I; Efstathiou, Jason; Galsky, Matthew; Grivas, Petros; Gupta, Shilpa; Haas, Naomi; Hakimi, A Ari; Hammers, Hans; Heng, Daniel Y C; Hirsch, Michelle; Iyer, Gopakumar; Jonasch, Eric; Koshkin, Vadim S; Kryvenko, Oleksandr; Lewis, Bryan; Li, Roger; Matin, Surena; Maughan, Benjamin; McDermott, David F; McGregor, Bradley; Meeks, Joshua; Milowsky, Matthew; Motzer, Robert; Necchi, Andrea; Petrylak, Dan; Porten, Sima; Powles, Thomas; Rini, Brian; Shuch, Brian; Siefker-Radtke, Arlene; Sonpavde, Guru; Sridhar, S Srikala; Suarez, Cristina; Tang, Chad; Tripathi, Abhishek; Van Der Heijden, Michiel S; Voss, Martin; Xu, Wenxin; Zhang, Tian; Rosenberg, Jonathan; Choueiri, Toni K

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

非小细胞肺癌软脑膜转移的演变格局:一项国际性、当代、多中心队列研究

Zheng, M M; Xia, Y; Pan, K; Sun, F; Tan, A C; Dong, X R; Tu, H Y; Tang, L B; Li, Y S; Yin, K; Borgeaud, M; Singhal, S; Zhu, E; Zhang, J; Nilsson, M; Wu, J; Gibbons, D L; Wakelee, H; Neal, J W; Lee, J; Vaporciyan, A A; Ringsurongkawong, W; Tran, H T; Zhang, R Z; Zhang, T; Zhou, Q; Zhong, W Z; Li, W; Zhang, Y C; Riess, J W; Addeo, A; Heymach, J V; Myall, N; Tan, D; Wu, Y L; Le, X

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

CheckMate 9ER 随机 III 期试验中,对纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

Motzer, R J; Escudier, B; Burotto, M; Powles, T; Apolo, A B; Bourlon, M T; Shah, A Y; Porta, C; Suárez, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; Scheffold, C; Askelson, M; Panzica, J; Zhang, J; van Kooten Losio, M; Choueiri, T K

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机 II 期试验,比较乐伐替尼联合依维莫司与卡博替尼治疗 PD-1 免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者的疗效(LenCabo)

Hahn, A W; Chahoud, J; Skelton, W P; Yuan, Y; Zurita-Saavedra, A J; Kovitz, C; Alhalabi, O; Campbell, M T; Jonasch, E; Lin, J K; Desai, M; Santos, M J M N; Hwang, H; Corn, P G; Msaouel, P; Tannir, N M

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies

MTAP缺失在癌基因驱动的非小细胞肺癌中很常见,并可能使肿瘤对PRMT5抑制剂和靶向治疗联合治疗敏感。

Aldea, M; Lenahan, S; Locquet, M-A; Liao, L; Gasparro, M; Gokhale, P C; Ghigna, M-R; Ionescu, D N; Odintsov, I; Ngo, K; Wang, X; Aziz, S; Pecci, F; Garbo, E; Ivanova, E; Nakazawa, S; Kulesza, J; Tsai, J A; Zullo, L; Lee, J; Zielinska, M; Simon, S; Han, D; Marinello, A; Li, G; Rossato de Almeida, G; Huang, J; Paoloni, F; Gariazzo, E; Santo, V; Remon, J; Marks, J A; LoPiccolo, J; Florez, N; Nishino, M; Ricciuti, B; Luo, J; Barbie, D A; Planchard, D; Rotow, J K; Barlesi, F; Graf, R P; Feng, W W; Besse, B; Paweletz, C; Sholl, L; Shaw, A T; Jänne, P A

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

利拉夫替尼选择性抑制FGFR2的临床耐药机制。

Ellis H, Balasooriya E R, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent F W, Zhen Y, Silveira V S, Sellers W R, Corcoran R B, Juric D, Bardeesy N

Advancing Battery Manufacturing: Synchrotron Characterization for Industry

推进电池制造:面向行业的同步辐射表征

Koh, Hyeongjun; Burrow, James N; D'Anna, Nicolò; Zhang, Haozhe; Beatriceveena, Tharigopala Vincent; Wang, Jiaqi; Lai, Jianwei; Chen, Yiming; Cabana, Jordi; Chan, Maria K Y; Crumlin, Ethan J; Fenter, Paul A; Fister, Timothy T; Liu, Di-Jia; Meng, Ying Shirley; Shpyrko, Oleg; Wiaderek, Kamila; Hatzell, Kelsey B

Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial

冷冻保存血小板与液态保存血小板治疗手术出血的比较:CLIP-II随机非劣效性临床试验

Reade, Michael C; Marks, Denese C; Howe, Belinda D; Bailey, Michael J; Bannon, Paul G; Eastwood, Glenn M; French, Craig J; Gattas, David J; Higgins, Alisa M; Holley, Anthony D; Hu, Raymond T; Irving, David O; Johnson, Lacey; McGuinness, Shay P; McQuilten, Zoe K; Royse, Alistair G; Smith, Julian A; Weinberg, Laurence; Wood, Erica M

Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer.

细胞外囊泡衍生的 miRNA-182-5p 可使胰腺癌中的巨噬细胞产生免疫抑制表型。

Singh Baldev, Gaur Pankaj, Bose Pritha, Zhang Yanjun, Li Yaoxiang, Zhang Zihao, Kandhavelu Jeyalakshmi, Klotzbier William, Jayatilake Meth, Bansal Shivani, Farhan Mohd, Deol Sunain, Banerjee Partha P, Unger Keith, Gupta Seema, Verma Vivek, Cheema Amrita K